Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session 2

95MO - Characteristics of patients with brain metastases from HER2-positive breast cancer

Date

08 May 2021

Session

Mini Oral session 2

Presenters

Elena Laakmann

Citation

Annals of Oncology (2021) 32 (suppl_2): S60-S78. 10.1016/annonc/annonc508

Authors

E. Laakmann1, I. Witzel2, T. Neunhöffer3, T. Park-Simon4, R. Weide5, K. Riecke2, A. Polasik6, M. Schmidt7, J. Puppe8, C. Mundhenke9, K. Lübbe10, T. Hesse11, M. Thill12, D. Zahm13, C. Denkert14, T. Fehm15, V. Nekljudova16, J. Rey17, S. Loibl17, V. Mueller2

Author affiliations

  • 1 Hamburg/DE
  • 2 UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, 20246 - Hamburg/DE
  • 3 HELIOS Dr. Host Schmidt Kliniken, Wiesbaden/DE
  • 4 Medizinische Hochschule Hannover (MHH), 30625 - Hannover/DE
  • 5 Praxis für Hämatologie und Onkologie Koblenz, 56068 - Koblenz/DE
  • 6 Universitätsklinikum Ulm, Ulm/DE
  • 7 Universitätsmedizin Mainz, Mainz/DE
  • 8 Universitätsklinikum Köln, 50937 - Köln/DE
  • 9 Klinikum Bayreuth GmbH, Bayreuth/DE
  • 10 Diakovere Henriettenstift, 30177 - Hannover/DE
  • 11 Agaplesion Diakonieklinikum, Rotenburg/DE
  • 12 Agaplesion Markus Krankenhaus, 60431 - Frankfurt am Main/DE
  • 13 SRH Wald-Klinikum Gera, Gera/DE
  • 14 Philipps-University Marburg, 35043 - Marburg/DE
  • 15 Universitätsklinikum Düsseldorf, 40255 - Düsseldorf/DE
  • 16 GBG, 63263 - Neu-Isenburg/DE
  • 17 German Breast Group (GBG) Forschungs GmbH, 63263 - Neu-Isenburg/DE
More

Resources

Login to access the resources on OncologyPRO.

Abstract 95MO

Background

About 40% of patients with a metastatic HER2+ breast cancer (BC) develop brain metastases (BM). A better understanding of clinical features of patients with HER2+ BC with BM is required.

Methods

A total of 2948 patients of the Brain Metastases in Breast Cancer (BMBC) Registry were available for this analysis, 1311 of them had a HER2+ subtype.

Results

Patients with a HER2+ BC and BM were,compared to HER2- patients, slightly younger at BC diagnosis (median 52 vs 53 years, p<0.001) and BM diagnosis (median 55 vs 58 years, p<0.001), had a higher pathological complete response rate after neoadjuvant chemotherapy (21.5 vs 12.2%, p=0.002), higher tumor grading (G3 59.5 vs 56.5%, p<0.001) and had less common extracranial metastases (ECM) at BM diagnosis (77.7 vs 80.0%, p<0.001). HER2+ patients had significantly more often BM in the posterior fossa (57.9 vs 49.0%, p<0.001) but less common leptomeningeal metastases (LM) (9.3 vs 19.1%, p<0.001). Hormone-receptor-positive HER2+ patients were younger at BC diagnosis (median 50 vs 53 years, p=0.03), had a smaller initial BC (<5cm: 78.4 vs 66.3%, p=0.002), a lower grading of the primary tumor (G1/G2: 46.1 vs 29.9%, p<0.001) and more often LM (11.3 vs 6.8%, p=0.007). The median overall survival (OS) in all HER2+ patients was 13.2 months (95% CI 11.4-14.4). The following factors were associated with a worse OS (multivariate analysis): older age (≥60 vs <60 years: Hazard Ratio [HR] 1.63, p<0.001), lower performance status (ECOG 2-4 vs 0-1: HR 1.58, p<0.001), greater number of BM (2-3 vs 1 BM: HR 1.36; ≥4 vs 1 BM: HR 1.53, p=0.003; overall p=0.012), BM in fossa anterior (HR 1.71, p<0.001), LM (HR 1.62, p=0.027), BM with neurological symptoms at diagnosis (HR 1.38, p=0.029), ECM at diagnosis of BM (HR 1.44, p=0.02) and the absence of targeted therapy (HR 0.625, p=0.001). Although progression-free survival did not differ in HER2+ patients according to hormone-receptor status, a significantly better OS could be observed for hormonereceptor-positive patients (median 14.3 vs 10.9 months, p=0.027).

Conclusions

The performed analysis identified factors associated with prognosis of HER2+ patients with BM. Further research is needed to understand the factors determining the longer survival of HER2+ hormonereceptor-positive patients.

Legal entity responsible for the study

German Breast Group Forschungs GmbH.

Funding

Has not received any funding.

Disclosure

I. Witzel: Honoraria (institution): Amgen; Honoraria (institution): AstraZeneca; Honoraria (institution): MSD; Honoraria (institution): Novartis; Honoraria (institution): Pierrre Fabre Pharma; Honoraria (institution): Pfizer; Honoraria (institution): Roche; Honoraria (institution): Sanofi-Pfizer. C. Denkert: Honoraria (institution), Oncobiome project: European Commission H2020; Honoraria (institution), INTEGRATE-TN project: German Cancer Aid Translational Oncology; Honoraria (self): Novartis; Honoraria (self): Roche; Honoraria (self): MSD Oncology; Honoraria (self): Daiichi Sankyo; Honoraria (self): AstraZeneca; Honoraria (self): Molecular Health; Honoraria (institution): Myriad; Honoraria (self): Merck; Shareholder/Stockholder/Stock options, Cofounder/shareholder until 2016: Sividon diagnostics; Licensing/Royalties: VMScope digital pathology software; Licensing/Royalties: WO2020109570A1 - cancer immunotherapy; Licensing/Royalties: WO2015114146A1 and WO2010076322A1- therapy response. S. Loibl: Honoraria (institution), honoraria for lectures and ad boards paid to institute: AbbVie; Honoraria (institution), honoraria for lectures and ad boards paid to institute: Celgene; Honoraria (institution), honorarium for lectures paid to institute: PriME/Medscape; Honoraria (self), lecture: Chugai; Honoraria (self), Honoraria (institution), honoraria paid to institute: Daiichi Sankyo; Honoraria (institution), honorarium for ad boards paid to institute: Lilly; Honoraria (institution), advisor honorarium paid to institute: BMS; Honoraria (institution), advisor honorarium paid to institute: Puma; Honoraria (institution), paid to institute: Immunomedics; Honoraria (institution), honorarium for lectures and ad boards paid to institute: AstraZeneca; Honoraria (institution), honorarium for lectures and ad boards paid to institute: Pierre Fabre; Honoraria (institution), honorarium for lectures and ad boards paid to institute: Merck; Honoraria (institution), advisor honorarium paid to institute: EirGenix; Honoraria (institution), honorarium for lectures and ad boards paid to institute: Amgen; Honoraria (institution), honorarium for lectures and ad boards paid to institute: Novartis; Honoraria (institution), honorarium for lectures and ad boards paid to institute: Pfizer; Honoraria (institution), grant and honorarium paid to institute: Roche; Honoraria (institution), paid to institute: Seagen; Licensing/Royalties, Immunsignature in TNBC: EP14153692.0. V. Mueller: Advisory/Consultancy: Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, Daiichi Sankyo, Eisai, Lilly, Tesaro and Nektar; Speaker Bureau/Expert testimony: Amgen, AstraZeneca, Daiichi Sankyo, Eisai, Pfizer, MSD, Novartis, Roche, Teva, Seagen and consultancy honoraria from Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, Daiichi Sankyo, Eisai, Lilly, Tesaro, Nektar; Honoraria (institution): Novartis, Roche, Seattle Genetics, Genentech. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings